OncoHeart Specialist Care’s Post

Author Dr Fermin Celma. GcMAF and Multiple Myeloma. A study investigated the effects of GcMAF on human multiple myeloma cells (KMS-12-BM) and human macrophages (CRL9853). The results showed that GcMAF decreased the viability of multiple myeloma cells in a dose-dependent manner. Additionally, GcMAF activated human macrophages, which then phagocytosed (engulfed and digested) the myeloma cancer cells. This dual action—direct inhibition of cancer cell viability and activation of macrophages—suggested that GcMAF could be a promising immunotherapeutic agent.I therefore trialed this in our clinic. We have many case studies from our clinic where GcMAF is one of the therapies that we implement. 1. A case study focused on a 55-year-old male with multiple myeloma. This study highlighted the importance of innovative treatments and potential for new therapies to improve patient outcomes. The patients presented with symptoms like exertional fatigue and were diagnosed with symptomatic multiple myeloma. The study emphasized the need for comprehensive diagnostic work-ups and personalized treatment plans to manage the disease effectively. 2. 2nd case study, we examined the effects of GcMAF on a patient with multiple myeloma. The patient received GcMAF treatment, which led to a significant reduction in tumour size and an improvement in overall health. This study clearly demonstrats that the patient experienced fewer symptoms and better quality of life with GcMAF. This case highlights the potential benefits of GcMAF as part of a comprehensive treatment plan for multiple myeloma. 3. Male 36 years old, very athletic. The big issue he presented with was shortness of breath, also called dyspnea, which is a common symptom of multiple myeloma, he had a persistent cough, which also caused some bleeding. He felt he couldn't breathe, which caused the symptoms to exasperate. Following the first session of nebuliser, he coughed more for 5 minutes, the cough soon subsided, and his breathing became more normalised. With each day that passed, the coughing decreased. His oxygen levels increased. Within one week, he gained a much better quality of life. He remained in close proximity for one month to the clinic. He left with a reduction of 30% and a better outlook. We implemented nebulised gcmaf with sub-c injection at 2500ng daily in this case. Since using Gcmaf for not only multiple myeloma but other types of cancers, our results have improved. Please note that GcMAF is legal to use in all forms of administration in Mexico. Also note that GcMAF only formed part of the protocol. Our double blind studies certainly have a better outcome with all forms of Cancer than those taking the plasibo. I find Gcmaf very useful in the cases of those on the spectrum of Autism, cancer, MS, parkinsonism, HIV, HSV and dementia. We purchased gcmaf from www.dubaibioremedix.com Author Dr Fermin Celma #Drfermincelma #gcmaf #multiplemyelomaawareness #cancerawareness #dubaibioremedix

🔬📊 Understanding the CA-19.9 Test: Clinical Significance in Diagnosing Pancreatic Cancer 🌟🧬 Let’s explore the importance of the CA-19.9 Test, a crucial biomarker for diagnosing and monitoring pancreatic cancer and other gastrointestinal cancers. What is the CA-19.9 Test? The CA-19.9 Test measures the level of the carbohydrate antigen 19-9 (CA-19.9) in the blood. Elevated levels of CA-19.9 can indicate the presence of pancreatic cancer, as well as other types of cancer, such as bile duct, gallbladder, and colorectal cancers. Sample Type Blood Serum Clinical Significance: 1.Diagnosing Pancreatic Cancer: The CA-19.9 Test is commonly used to help diagnose pancreatic cancer. While not definitive, elevated levels of CA-19.9 can prompt further diagnostic investigations, such as imaging studies and biopsies. 2.Monitoring Treatment Response: For patients with confirmed pancreatic cancer, the CA-19.9 Test is valuable in monitoring the effectiveness of treatment. A decrease in CA-19.9 levels often indicates a positive response to therapy, while increasing levels may suggest disease progression. 3.Assessing Recurrence: After successful treatment, regular CA-19.9 testing can help detect cancer recurrence. Rising levels of CA-19.9 in a previously treated patient may warrant further diagnostic evaluation. Patient Impact and Clinical Considerations: 1.Early Detection: Although not specific enough for early screening, the CA-19.9 Test can aid in the early detection of pancreatic cancer when used alongside other diagnostic tools, improving the chances of successful treatment. 2.Personalized Treatment Plans: By monitoring CA-19.9 levels, healthcare providers can tailor treatment plans based on individual patient responses, optimizing therapeutic outcomes. 3.Holistic Patient Care: Regular monitoring of CA-19.9 levels supports comprehensive patient care, ensuring timely interventions and continuous assessment of the disease status. The CA-19.9 Test is a vital tool in the fight against pancreatic cancer and other gastrointestinal malignancies. Join me in recognizing the significance of the CA-19.9 Test and its impact on advancing cancer care. 🌍🔬 ⚕️I’m Dennis Odoi empowering you to seize control of your health. ⚕️Follow along to join a community of like-minded commanders. ♻️ Repost to save a life #CancerDiagnosis #CA199Test #PancreaticCancer #ClinicalSignificance #HealthcareInnovation Day 157/366 Days

“Liver cancer : Types”.... They can be classified into several types based on the origin and nature of the cancerous cells. The main types of liver cancer include: Primary Liver Cancer 1. **Hepatocellular Carcinoma (HCC)** - ** Description**: The most common type of primary liver cancer, accounting for about 75-85% of cases. - **Origin**: Arises from hepatocytes, the main type of liver cells. - **Characteristics**: Often associated with chronic liver diseases such as hepatitis B, hepatitis C, and cirrhosis. 2. **Intrahepatic Cholangiocarcinoma (Bile Duct Cancer)** - **Description**: Comprises about 10-20% of primary liver cancers. - **Origin**: Develops from the cells lining the bile ducts within the liver. - **Characteristics**: Symptoms often overlap with those of HCC but can also include jaundice and changes in stool and urine color. 3. **Hepatoblastoma** - **Description**: A rare type of liver cancer that typically affects children under the age of 3. - **Origin**: Believed to arise from immature liver precursor cells. - **Characteristics**: Presents as an abdominal mass, with symptoms such as abdominal swelling, pain, and sometimes jaundice. 4. **Angiosarcoma and Hemangiosarcoma** - **Description**: Very rare types of cancer that originate in the blood vessels of the liver. - **Origin**: Arise from endothelial cells lining the blood vessels. - **Characteristics**: Often aggressive and difficult to diagnose early due to the rapid progression and nonspecific symptoms like pain and weight loss. Secondary (Metastatic) Liver Cancer - **Description**: Cancer that has spread to the liver from other parts of the body. - **Common Primary Sites**: Often metastasizes from cancers of the colon, pancreas, lung, breast, or stomach. - **Characteristics**: Symptoms may include those of primary liver cancer, such as pain and jaundice, as well as symptoms associated with the primary cancer. Benign Liver Tumors... Though not cancerous. 1. **Hemangiomas** 2. **Hepatic Adenomas** 3. **Focal Nodular Hyperplasia (FNH)** Dr. Kshitij Manerikar Hepatobiliary Cancer Surgeon.

Only a fraction of eligible veterans—3.9%—received lung cancer screening (LCS) before their diagnosis, yet this small group experienced significant benefits. Donna M. Edwards and colleagues published a groundbreaking study in Cancer (2024) that sheds light on the real-world impact of lung cancer screening within the Veterans Health Administration (VA). With lung cancer remaining the leading cause of cancer deaths globally, this study highlights how low-dose CT scans could revolutionize early detection and outcomes. 📊 Key Findings: - Stage Shift: Screened patients were twice as likely to be diagnosed at stage I (52% vs. 27%) and less likely at stage IV (11% vs. 32%). - Survival Rates: Five-year overall survival was markedly higher for screened patients (44.9% vs. 22.3%). Lung cancer-specific survival was also better (59.0% vs. 29.7%). - Mortality Reduction: For screening-eligible veterans, screening decreased lung cancer-specific mortality by 39% (adjusted hazard ratio [aHR] 0.61). Why It Matters: Despite robust evidence supporting LCS, uptake remains limited. Barriers like provider concerns over overdiagnosis and systemic challenges hinder its widespread adoption. Yet, the data underscores that early detection saves lives—highlighting the urgency for broader implementation. 🧠 My Thoughts: As radiologists, we’re accustomed to detecting abnormalities in their earliest stages, and this study reinforces our role in driving innovation. However, we must tackle the persistent challenge of integrating effective screening programs across diverse healthcare systems. The findings call for not only systemic support but also informed dialogue about implementing AI and advanced diagnostics to ensure no patient is left behind. What’s your take? How can we address the barriers to lung cancer screening in real-world practice? Share your thoughts below! Link to the article: https://lnkd.in/d7zDu-fx Read more: https://lnkd.in/d-AYK2re

When I initiated a 1000-patient lung cancer survey across 9 countries at Novartis a few years ago, in collaboration with cross-functional colleagues and patient advocates, it served to better understand the bigger landscape of patient experience without being tied to a single product or brand. Although there were many lung cancer clinical trials at various stages, what was clear, was that we could not truly transform the care of people living with lung cancer if we did not understand their core needs within their healthcare systems. Along with my co-authors Andrew Ciupek, Lorraine Dallas, Pasquale Varriale, PhD, and Julie Laurent - a mix of patient advocates, patient experience research and digital patient community specialists - we are proud to share the publication! I especially want to thank the senior author, Andrew Ciupek from the GO2 Foundation for Lung Cancer, whose exceptional expertise and insights from patient advocacy really helped to shape how we discussed the relevance of the data to the real world realities of people living with lung cancer 🙌 Frank, P., Laurent, J., Dallas, L. et al. Experience and Care Pathway of Patients with Lung Cancer: An Online International Survey. Oncol Ther (2024). https://lnkd.in/ed-a_6gt Key Learnings for me from this research: 👩💻 Access to information, therapies and supportive services in lung cancer is still widely disparate, and it is not just related to a country being high vs low or middle income. 👴 We often hear of bias in terms of race/ethnicity, however, we uncovered additional bias in older populations. 🚧 Systemic barriers or enablers like access to genetic and biomarker testing, seem to be linked to participation in clinical trials. 🙋♀️More patients wanted to participate in clinical trials, than were actually asked. 👨👩👧👧 Family members have a significant role in quality-of-life discussions, and their involvement can support multi-disciplinary teams. 🧑💼We had a good representation of younger patients, which added to the impact on employment and mental well-being from lung cancer. 👥 Although clinically the different types of lung cancer have their defined approach to management, the preferences of those living with lung cancer are quite similar across types. 🛜 Starting with patient unmet needs, digital health solutions can be useful to help address them. Additional thanks to Ortal Barziv MD. who was the Medical Lead for this research before her transition to a new role outside of Novartis, and to James Warburton and the broader Lung Cancer Global Program Team at Novartis for their support to progress the publication after organisational changes. We hope these insights support the movement to a better care pathway for those living with lung cancer! #lungcancer #patientengagement #patientperspective #PED #patientpreferences #unmetneed #survey #clinicaltrials #novartis #DEI #digitalhealth #QoL #MDT #precisionmedicine @Carenity

📃Scientific paper: Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study Abstract: BACKGROUND: Treatment of cancer patients in certified cancer centers, that meet specific quality standards in term of structures and procedures of medical care, is a national treatment goal in Germany. However, convincing evidence that treatment in certified cancer centers is associated with better outcomes in patients with pancreatic cancer is still missing. METHODS: We used patient-specific information (demographic characteristics, diagnoses, treatments) from German statutory health insurance data covering the period 2009–2017 and hospital characteristics from the German Standardized Quality Reports. We investigated differences in survival between patients treated in hospitals with and without pancreatic cancer center certification by the German Cancer Society (GCS) using the Kaplan–Meier estimator and Cox regression with shared frailty. RESULTS: The final sample included 45,318 patients with pancreatic cancer treated in 1,051 hospitals (96 GCS-certified, 955 not GCS-certified). 5,426 (12.0%) of the patients were treated in GCS-certified pancreatic cancer centers. Patients treated in certified and non-certified hospitals had similar distributions of age, sex, and comorbidities. Median survival was 8.0 months in GCS-certified pancreatic cancer centers and 4.4 months in non-certified hospitals. Cox regression adjusting for multiple patient and hospital characteristics yielded a significantly lower hazard of long-term, all-cause mortality in patients treated in GCS-c... Continued on ES/IODE ➡️ https://etcse.fr/5B1 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

How many informative facts about colorectal cancer do you know? Are you ready to take on the challenge? Grab a pencil and paper and answer the questions below. Remember, it's okay if you don't get everything correct; this quiz aims to test your knowledge and help you better understand colorectal cancer. 1. Colorectal cancer develops rapidly, True or False. 2. Colorectal cancer can be prevented if detected early, True or False. 3. Regular screening helps identify the disease in its early stages when it is most treatable, True or False. 4. The ACS recommends that people at average risk of colorectal cancer start regular screening at age 55. Test and see how well you did. For those who answered some questions incorrectly, let's look at a few statistics surrounding women's health. Visit the following link: https://lnkd.in/eRqF6ze4 Answers: 1. False 2. True 3. True 4. True 5. False Screening for colorectal cancer is important for several compelling reasons. Firstly, early detection significantly increases the chances of successful treatment and improves outcomes. Colorectal cancer often develops slowly over several years, starting as benign polyps that can be detected and removed during routine screening tests such as colonoscopies. By identifying and removing these precancerous growths, individuals can effectively prevent the development of colorectal cancer or catch it at an early stage when treatment is most effective. Secondly, colorectal cancer is one of the most common and deadly forms of cancer worldwide. Regular screening helps identify the disease in its early stages when it is most treatable, potentially saving lives. Studies have shown that screening reduces both the incidence of colorectal cancer and mortality rates associated with the disease. Furthermore, many individuals with colorectal cancer do not experience symptoms in the early stages of the disease. By the time symptoms such as rectal bleeding, changes in bowel habits, or abdominal pain manifest, the cancer may have already advanced to a more aggressive stage, making treatment more challenging. Screening tests enable the detection of colorectal cancer before symptoms appear, allowing for prompt intervention and better outcomes. The ACS recommends that people at average risk of colorectal cancer start regular screening at age 45. This can be done either with a sensitive test that looks for signs of cancer in a person's stool (a stool-based test) or with an exam that looks at the colon and rectum (a visual exam). Certain risk factors for colorectal cancer, such as age and family history, are beyond individual control; screening provides an opportunity for early detection and intervention regardless of risk factors. Therefore, individuals must undergo regular screening, as recommended by healthcare professionals, based on factors such as age, family history, and other risk factors.

🌟#EpiTales # 31🌟 🔲 Do antimuscarinic medications cause cancer? Protopathic Bias?🔲 Mohamed: "Dr. X, I came across a study linking medications for overactive bladder to an increased risk of cancer. How could that be?" Dr. X: "Ah, Mohamed, this might be a case of Protopathic Bias! It's when early symptoms of a disease are mistaken for risk factors. Let's look at a real publication to understand it better." Mohamed: "I'm intrigued! What's the example?" Dr. X: "In a study by Kaye et al. (2017), researchers investigated cancer incidence among patients using antimuscarinic medications for overactive bladder. They found that the incidence rates of prostate and bladder cancer were significantly higher in the first year after starting the medication." Mohamed: "So, the medications were thought to cause cancer?" Dr. X: "Initially, yes. But further analysis revealed that these patients' urinary symptoms, which prompted the prescription of antimuscarinic medications, were actually early signs of undiagnosed cancers. The medications didn't cause cancer; the early symptoms did." Mohamed: "Wow! So, the early symptoms were mistaken for risk factors. That's Protopathic Bias in action!" Dr. X: "Exactly, Mohamed! Here's the data: In the first year, the incidence rate of prostate cancer was 14.2 per 1000 person-years, which dropped to 6.8 per 1000 person-years in the second year. Similarly, bladder cancer incidence rates were higher in the first year at 5.5 for men and 1.2 for women per 1000 person-years, decreasing markedly thereafter." Mohamed: "That's fascinating! It shows how important it is to consider the timeline of symptom onset and treatment." Dr. X: "Indeed, Mohamed! Always consider the timeline of symptoms and treatments to avoid Protopathic Bias. 📅" ------------------------------------------------------------------------------------ "I share daily insights on Epidemiology. Follow my #EpiTales for engaging stories, #EpiTools for practical Shiny apps, and #EpiNews for the latest updates!"

The balance between Tregs and Th17 cells and its role in the development of follicular thyroid cancer. - Thyroid cancer is one of the most common malignant tumors, with a noticeable increase in incidence rates globally in recent years. Among its various types, papillary thyroid cancer (PTC) is the most predominant and requires effective management to achieve better patient survival outcomes. This article addresses the role of T1-17 helper cells (Th17) and regulatory T cells (Tregs) in papillary thyroid cancer, highlighting the delicate balance between them and their impact on disease progression. We will also explore how monoclonal antibodies targeting immune checkpoints can be employed as a new option for prevention and treatment. Through this discussion, we aim to provide insights into the challenges of treating this disease and offer new therapeutic options to improve patient outcomes. Thyroid Cancer and its Common Pattern Thyroid cancer is one of the most common types of cancer in the head and neck region. According to statistics, the number of patients diagnosed with this type of cancer is approximately 586,000 worldwide in 2020. Thyroid cancer ranks ninth in incidence rates among malignant tumors. Over the years, there has been a noticeable increase in cases of thyroid cancer globally, particularly in China, where the country recorded a significant rise in the number of cases from 2005 to 2015. Papillary thyroid cancer (PTC) is the most common form of this cancer, representing about 90% of new cases. Surgical resection is considered the standard treatment for this type of cancer, as patients who undergo surgery have better survival outcomes, reaching up to 93% over ten years. However, between 30% to 40% of papillary thyroid cancer cases experience cancer spread to regional lymph nodes, which is associated with poorer survival prognoses. Therefore, the recurrence rate of thyroid cancer with lymph node metastasis is 3.5 times higher compared to patients without metastasis. Despite the good performance of surgical treatment, some patients are found to have distant metastasis at the initial diagnosis. Research indicates that 2% of patients may experience distant metastasis when starting treatment, with common metastatic sites including the lungs, bones, liver, and brain. These facts highlight the necessity to look for new molecular markers and therapeutic targets to improve treatment efficacy and enhance patient outcomes. The Immune System and its Role in Papillary Thyroid Cancer The immune system plays a vital role in tumor development and survival, including in papillary thyroid cancer. Th17 cells and regulatory T cells (Tregs) are significant components of the immune system that influence disease progression. Th17 cells secrete pro-inflammatory cytokines, while Tregs play a role in suppressing the immune response. The balance between these two cell types significantly affects cancer progression. Th17 cells are responsible ...

𝗧𝗵𝗲 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝗰𝗲 𝗼𝗳 𝗘𝗮𝗿𝗹𝘆 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 Early cancer detection can save lives. When cancer is found in its early stages, treatment is more effective, survival rates are higher, and patients often have a better quality of life. Despite advances in cancer treatment, detecting cancer early remains one of the most important factors in improving outcomes. Here’s why early detection matters and how it can make a difference: 𝟭. 𝗕𝗲𝘁𝘁𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗢𝘂𝘁𝗰𝗼𝗺e When cancer is detected early, it allows for less aggressive treatment, fewer side effects, and a higher chance of success. For many cancers, such as breast, cervical, and colorectal cancers, early detection significantly improves survival rates. 𝟮. 𝗠𝗼𝗿𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗢𝗽𝘁𝗶𝗼𝗻𝘀 With early-stage cancer, patients often have more treatment options available to them, including less invasive procedures. In some cases, early detection can prevent the need for major surgery or long-term chemotherapy, reducing the overall burden of treatment. 𝟯. 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝘀𝘁𝘀 Treating cancer in its later stages is not only more complex but also more expensive. Early detection can help reduce healthcare costs by allowing for simpler and shorter treatments. Preventative screenings and early diagnosis are cost-effective ways to manage cancer. 𝟰. 𝗜𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝗟𝗶𝗳𝗲 Early intervention can reduce the physical and emotional toll that comes with more advanced-stage cancers. 𝟱. 𝗥𝗲𝗴𝘂𝗹𝗮𝗿 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴𝘀 𝗦𝗮𝘃𝗲 𝗟𝗶𝘃𝗲𝘀 Routine screenings, such as mammograms, Pap smears, colonoscopies, and prostate specific antigen (PSA) tests, are key to early detection. These tests can catch cancers before symptoms appear, giving patients the best chance of a successful outcome. Be sure to follow screening guidelines based on your age, gender, and family history. 𝟲. 𝗞𝗻𝗼𝘄 𝘁𝗵𝗲 𝗪𝗮𝗿𝗻𝗶𝗻𝗴 𝗦𝗶𝗴𝗻𝘀 In addition to regular screenings, it’s crucial to be aware of the potential warning signs of cancer, such as unexplained weight loss, persistent fatigue, changes in the skin, unusual lumps, or prolonged pain. 𝟳. 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗶𝘀𝘁𝘀 𝗮𝘀 𝗘𝗮𝗿𝗹𝘆 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗔𝗱𝘃𝗼𝗰𝗮𝘁𝗲𝘀 Pharmacists can also play a vital role in early cancer detection. They are accessible healthcare professionals who can educate patients about the importance of screenings, help them understand their risk factors, and provide guidance on what to do if they notice potential warning signs. Don’t hesitate to ask your pharmacist about cancer screenings—they’re here to help. Stay proactive, ask your healthcare provider about screening options, and take charge of your health. If you have questions about cancer screenings, speak to your #pharmacist or healthcare team today. Early detection could save your life.